Q32 Bio (QTTB) Cash & Current Investments (2017 - 2026)
Q32 Bio (QTTB) recorded quarterly Cash & Current Investments of $50.8 million in Q1 2026, up 5.08% quarter-over-quarter from $48.3 million in Q4 2025, and down 22.5% on a YoY basis from $65.5 million in Q1 2025.
Q32 Bio (QTTB) Cash & Current Investments (2017 - 2026) Analysis & Trends
Q32 Bio's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $50.8 million for Q1 2026.
- In Q1 2026, Cash & Current Investments fell 22.5% year-over-year to $50.8 million; the TTM figure through Mar 2026 stood at $50.8 million (down 22.5% YoY), while the FY2025 annual figure was $48.3 million, down 38.05% from the prior year.
- Cash & Current Investments was $50.8 million for Q1 2026 at Q32 Bio, up from $48.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $256.1 million in Q1 2022 to a low of $25.6 million in Q4 2023.
- Historically, Cash & Current Investments has averaged $112.0 million across 5 years, with a median of $89.1 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 85.36% in 2023, then jumped 204.35% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $175.0 million in 2022, then plunged by 85.36% to $25.6 million in 2023, then surged by 204.35% to $78.0 million in 2024, then slumped by 38.05% to $48.3 million in 2025, then increased by 5.08% to $50.8 million in 2026.
- The last three Cash & Current Investments figures came in at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $68.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | 50.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.75 Mn |
| Dec 31, 2025 | 48.30 Mn |
| Sep 30, 2025 | 68.94 Mn |
| Jun 30, 2025 | 54.83 Mn |
| Mar 31, 2025 | 65.48 Mn |
| Dec 31, 2024 | 77.97 Mn |
| Sep 30, 2024 | 89.08 Mn |
| Jun 30, 2024 | 107.65 Mn |
| Mar 31, 2024 | 135.31 Mn |
| Dec 31, 2023 | 25.62 Mn |
| Sep 30, 2023 | 110.44 Mn |
| Jun 30, 2023 | 70.33 Mn |
| Mar 31, 2023 | 141.98 Mn |
| Dec 31, 2022 | 175.03 Mn |
| Sep 30, 2022 | 201.07 Mn |
| Jun 30, 2022 | 225.52 Mn |
| Mar 31, 2022 | 256.13 Mn |
| Dec 31, 2021 | 157.83 Mn |
| Sep 30, 2021 | 187.55 Mn |
| Jun 30, 2021 | 214.57 Mn |